TriSalus Life Sciences, Inc. (TLSI) Stock Score, Valuation & Financial Research
TriSalus Life Sciences, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 28/100.
Quick answer for TLSI
TriSalus Life Sciences, Inc. currently has a Wall Street Score of 28/100. The stored market price is $4.67. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What TriSalus Life Sciences, Inc. does
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's
TLSI financial snapshot
- Wall Street Score:
- 28/100
- Current price:
- $4.67
- Market capitalization:
- $287.2M
- Revenue:
- $44.9M
- Net income:
- $-27.3M
- Free cash flow:
- $-18.9M
- Cash:
- $56.6M
- Total debt:
- $34.5M
- EPS:
- -1.84
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 23/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $-18.9M, showing cash burn in the current stored period.
- The balance sheet shows $56.6M of cash versus $34.5M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research TLSI
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.